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Abstract
Although there has been increasing interest in the use of high protein diets, little is known
about dietary protein related changes in the mammalian metabolome. We investigated the
influence of protein intake on selected tryptophan and phenolic compounds, derived from
both endogenous and colonic microbial metabolism. Furthermore, potential inter-species
metabolic differences were studied. For this purpose, 29 healthy subjects were allocated to
a high (n = 14) or low protein diet (n = 15) for 2 weeks. In addition, 20 wild-type FVB mice
were randomized to a high protein or control diet for 21 days. Plasma and urine samples
were analyzed with liquid chromatography–mass spectrometry for measurement of trypto-
phan and phenolic metabolites. In human subjects, we observed significant changes in
plasma level and urinary excretion of indoxyl sulfate (P 0.004 and P 0.001), and in urinary
excretion of indoxyl glucuronide (P 0.01), kynurenic acid (P 0.006) and quinolinic acid (P
0.02). In mice, significant differences were noted in plasma tryptophan (P 0.03), indole-3-
acetic acid (P 0.02), p-cresyl glucuronide (P 0.03), phenyl sulfate (P 0.004) and phenylace-
tic acid (P 0.01). Thus, dietary protein intake affects plasma levels and generation of various
mammalian metabolites, suggesting an influence on both endogenous and colonic micro-
bial metabolism. Metabolite changes are dissimilar between human subjects and mice,
pointing to inter-species metabolic differences with respect to protein intake.
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Introduction
In an ongoing quest for the optimal diet and when taken into account the epidemic of obesity,
there has been an increasing interest in diets low in carbohydrate with a concomitant high
intake of protein. Although effective in inducing weight loss [1], there remains controversy
whether these high protein diets are beneficial or may even cause harm to human health on the
long term [2, 3]. In the nephrology community, there has also been a continuous debate about
the ideal target of dietary protein intake in patients with chronic kidney disease (CKD). Mecha-
nistic studies have demonstrated that high protein diets are associated with glomerular hyper-
filtration, which could further compromise renal function of patients with pre-existing renal
disease [4, 5]. Although criticized [6], meta-analyses of interventional studies also concluded
that a low protein diet attenuates progression of CKD [7–9].
In addition, it can be hypothesized that dietary protein intake affects various health condi-
tions by influencing the mammalian metabolome. For example, the tryptophan—kynurenine
pathway has been related with inflammation and cardiovascular disease, both in the general
population and patients with CKD, possibly due to activation of the aryl hydrocarbon receptor
[10–12]. Recently, it has also been demonstrated that tryptophan metabolites may predict new-
onset renal disease [13]. Furthermore, there has been mounting evidence that microbial metab-
olites originating from colonic protein fermentation play a pivotal role in the pathogenesis of
adverse outcomes in patients with CKD. Both indoxyl sulfate, a tryptophan metabolite, and p-
cresyl sulfate, a phenolic compound, have repeatedly been associated with overall mortality
and cardiovascular disease [14–19], as well as with progression of CKD [20], giving rise to the
so-called protein metabolite theory [21].
Of note, the impact of dietary protein intake on these and other relevant metabolites has not
been fully elucidated. Moreover, it must be acknowledged that changes in protein intake will
only influence the colonic fermentation process when associated with concomitant changes in
colonic protein availability [22], thus largely depending on small intestinal assimilation capac-
ity. Therefore, we aimed to explore the influence of dietary protein intake on the mammalian
metabolome, focusing on selected tryptophan and phenolic compounds derived from both
endogenous and colonic microbial metabolism. For this purpose, we exposed healthy human
subjects and mice to either a high protein or control diet. This also allowed us to examine
potential inter-species metabolic differences with respect to protein intake.
Material and Methods
Clinical study: population
This is a secondary analysis of a previous randomized controlled trial exploring the influence
of dietary protein intake on fecal water toxicity (clinicaltrials.gov NCT01280513) [23]. After a
pilot study in 9 healthy subjects, the original study included 20 subjects. For this analysis, we
used the combined dataset, giving a total of 29 subjects. Participants were recruited by adver-
tisement among students and employees of the University of Leuven. Exclusion criteria
included history of abdominal surgery (with the exception of appendectomy), presence of gas-
tro-intestinal disease (i.e., inflammatory bowel disease, irritable bowel disease or celiac disease),
or presence of renal disease (i.e., estimated glomerular filtration rate (CKD-EPI) below 60 mL/
min/1.73m2). Drug therapy influencing colonic transit or microbiota (i.e., pre-, pro- or antibi-
otics) was prohibited 1 month before and during study period. The study was performed
according to the Declaration of Helsinki and approved by the ethics committee of the Univer-
sity Hospitals Leuven. Written informed consent was obtained from all subjects.
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Clinical study: design
After a 2-week run-in period, during which the subjects consumed their habitual normal pro-
tein diet, each subject was randomly assigned to receive either a high protein diet (HP group;
i.e., target of> 25% of total energy intake derived from protein intake) or a low protein diet
(LP group; i.e., target of 9%). During the first week of the run-in period, the subjects completed
a 7-day dietary record, allowing us to calculate total energy intake and dietary macronutrient
composition. With this information, we composed individually adapted diets, isocaloric to the
habitual diet of the subjects and taking into account personal preferences. In the HP group,
diet was also supplemented with 20 g protein powder per day (Resource, Nestlé Healthcare
Nutrition, Switzerland), while protein was replaced by digestible carbohydrates in the LP
group. Additionally, in both treatment groups, we aimed to keep fat and fiber intake as con-
stant as possible. These individually adapted diets were presented to the subjects by giving each
of them 3 lists with 7 suggestions for breakfast, lunch and dinner, respectively. Depending on
their caloric needs, they were also allowed to choose two or three snacks from a 4th list. During
the second week of intervention the subjects again completed a 7-day dietary record to evaluate
the actual food intake. During the run-in period and at the end of the intervention period, we
also collected blood after an overnight fast and urine (48h urinary collection) of each subject.
All samples were stored at– 80°C until further analysis.
Preclinical study: design
Wild-type Friend leukemia virus B (FVB) mice were bred and housed at the Central Animal
Laboratory of the Radboud University Medical Center. Animals were divided in two groups of
10 animals and provided either a control diet (21% crude protein) or a high protein diet (45%
crude protein; Ssniff Spezialdiäten GmbH, Soest, Germany) for 21 days. All animals had free
access to food and water. After 21 days, blood was collected in lithium-heparin tubes by cardiac
puncture under isoflurane anesthesia and animals were sacrificed by cervical dislocation.
Plasma was immediately snap frozen in liquid nitrogen and stored at– 80°C until further analy-
sis. All experiments were approved by the local Animal Welfare Committee of the Radboud
University Medical Center (RU-DEC 2012–292), in accordance with the directive for animal
experiments (2010/63/EU) of the European Parliament.
Analytical procedures
Dietary records were analyzed using the online food calculator ‘Nubel’ and information on stan-
dardized quantification of food products. Blood and urine human samples were used to measure
creatinine and urea with standard laboratory techniques. In addition, human and mice samples
were analyzed for a panel of metabolites, focusing on selected tryptophan and phenolic com-
pounds. All analyses were based on single measurements. With respect to the tryptophan metabo-
lites, we measured tryptophan, indoxyl sulfate, indoxyl glucuronide, indole-3-acetic acid,
kynurenine, kynurenic acid and quinolinic acid. Phenolic compounds included p-cresyl sulfate, p-
cresyl glucuronide, phenyl sulfate, phenyl glucuronide and phenylacetic acid. All metabolites were
quantified using a dedicated liquid chromatography—tandemmass spectrometry (LC-MS/MS)
method. Deuterated kynurenic acid was added as an internal standard for quantification, as
described previously [24]. Before chromatography an aliquot of plasma was diluted in H2O (1:1)
and deproteinized with perchloric acid (final concentration 3.3% (v/v)). Next, samples were cen-
trifuged at 12,000 x g for 3 min. Clear supernatant was injected into the LC-MS/MS system that
consisted of an Accela HPLC system coupled to a TSQ Vantage triple quadropole mass spectrom-
eter (Thermo Fischer Scientific, Breda, the Netherlands) equipped with a C18 HPLC column
(Acquity UPLC HSS T3 1.8 μm;Waters, Milford, MA). The autosampler temperature was set at
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8°C and the column temperature at 40°C. The flow rate was 350 μL/min. Eluent solvent A con-
sisted of 10 mMNH4-acetate, solvent B was 5 mMNH4-acetate and 0.1% formic acid and solvent
C was 100%methanol. Samples (10 μL) were injected three times. The first injection addressed
the basic negative components, including indoxyl sulfate, p-cresyl sulfate, phenyl sulfate and phe-
nylacetic acid, because these components are stable within the acidic environment for up to 16h.
The second injection addressed the acidic negative components, including indoxyl glucuronide,
quinolinic acid, p-cresyl glucuronide and phenyl glucuronide. The third injection addressed the
acidic positive components tryptophan, indole-3-acetic acid, kynurenine, kynurenic acid and qui-
nolinic acid. The elution gradient was as follows: for the first injection the gradient was 100% sol-
vent A to 85% solvent C in 7 min, then for the second and third injection a gradient of 100%
solvent B to 85% solvent C in 7 min. The effluent from the UPLC was passed directly into the elec-
trospray ion source. Negative electrospray ionization (first two injections) achieved using a nitro-
gen sheath gas with ionization voltage at 2500 Volt. The positive (third injection) electrospray
ionization was achieved using a nitrogen sheath gas with ionization voltage at 3500 Volt. The cap-
illary temperature was set at 240°C. Detection of the components was based on isolation of the
deprotonated (negative electrospray; [M-H]-) or protonated molecular ion (positive electrospray;
[M+H]+) and subsequent MS/MS fragmentations and a selected reaction monitoring (SRM) were
carried out. The UPLC-MS/MS operating conditions and SRM transitions used for parent com-
pounds and ion products were optimized for each component and shown in Table 1.
With the 48h urinary collection of human subjects, we calculated the average daily urinary
excretion of each metabolite, giving an estimate of its daily generation. Urinary collections
were considered complete when urinary excretion of creatinine was within 2 standard devia-
tions of the mean creatinine excretion for the geographical region of this study, derived from
the INTERSALT study [25].
Statistical analysis
Data are expressed as mean (standard deviation) for normally distributed variables or median
(interquartile range: IQR) for non-normally distributed variables. Differences in demographic
and dietary variables according to treatment group (HP vs. LP group) were tested using Stu-
dent’s t-test, Wilcoxon rank-sum test or chi-squared test as appropriate. Changes in human sol-
ute levels (post-intervention minus baseline) were correlated with changes in dietary protein
intake with Spearman's rank correlation coefficient, as well as compared with respect to treat-
ment group usingWilcoxon rank-sum test. Differences in mice solute levels (post-intervention)
between treatment groups (HP vs. control diet group) were also tested with Wilcoxon rank-sum
test. For all statistical analysis, P-values less than 0.05 were considered significant. All statistical
analyses were performed using SAS (version 9.3, the SAS institute, Cary, NC, USA).
Results
Study population: Demographic and dietary characteristics
A total of 29 healthy subjects were included for analysis. Of these, 14 subjects received a high
protein diet and 15 subjects were allocated to a low protein diet (Table 2). There were no signif-
icant differences in age, gender and body mass index between both groups. During the run-in
period, we observed no differences in both total energy intake and macronutrient intake (i.e.,
protein, carbohydrate, fiber and fat intake). On the other hand, as intended, protein intake was
significantly higher during intervention in the HP group (median of 124.6 g/day (122.7–167.0)
or 1.9 g/kg/day (1.9–2.3)) than in the LP group (50.0 g/day (43.3–58.5) or 0.8 g/kg/day (0.7–
1.0)) (P< 0.0001). Relative energy intake from dietary protein amounted to a median of 27%
(IQR 25–29) in the HP group vs. 13% (IQR 12–13) in the LP group. Plasma urea and 24h
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urinary excretion of urea also significantly increased in the HP vs. LP group (P< 0.0001 and P
0.0002, respectively; Fig 1). Total energy intake, fiber intake and fat intake were not statistically
different between both groups.
Tryptophan metabolites
We investigated the influence of dietary protein intake on the tryptophan metabolites. When
correlating changes in protein intake during intervention with changes in plasma level and 24h
urinary excretion of the various metabolites, we noted significant correlations with 24h urinary
excretion of tryptophan (ρ 0.47, P 0.01), plasma indoxyl sulfate (ρ 0.56, P 0.002), 24h urinary
Table 1. UPLC-MS/MS operating conditions.
Ionization mode m/z parent m/z product 1 CE 1 (eV) m/z product 2 CE 2 (eV) S-lens RF amplitude (V)
Phenyl acetic acid BN 135 91 8 - - 40
Phenyl sulfate BN 173 80 19 93 20 86
p-Cresyl sylfate BN 187 80 19 107 23 81
Indoxyl sulfate BN 212 80 23 132 23 96
Quinolinic acid AN 166 78 16 122 11 36
Phenyl glucuronide AN 269 93 42 113 13 95
p-Cresyl glucuronide AN 283 107 37 113 14 74
Indoxyl glucuronide AN 308 113 17 132 26 94
Quinolinic acid AP 168 78 23 124 11 62
Indole-3-acetic acid AP 176 77 42 130 16 65
Kynurenic acid AP 190 89 39 144 39 64
d5-Kynurenic acid AP 195 121 33 149 21 102
Tryptophan AP 205 146 18 188 10 54
Kynurenine AP 209 146 20 192 9 56
Abbreviations: UPLC-MS/MS, ultra-performance liquid chromatography—tandem mass spectrometry; m/z, mass-to-charge ratio; CE, collision energy; RF,
radiofrequency; BN, basic negative; AN, acidic negative; AP, acidic positive
doi:10.1371/journal.pone.0140820.t001
Table 2. Study population.
Variable Overall (n = 29) High protein (n = 14) Low protein (n = 15) P
Age (y) 22 (20–23) 22 (21–23) 21 (19–24) 0.58
Gender: male/female (%) 9/20 (31.0/69.0) 3/11 (21.4/78.6) 6/9 (40.0/60.0) 0.43
Body mass index (kg/m2) 21.03 (19.61–22.91) 22.56 (20.55–23.18) 20.98 (19.57–22.23) 0.23
Run-in diet:
Calories (Kcal/day) 2053.8 (379.4) 2023.1 (322.0) 2082.3 (435.7) 0.68
Protein (g/day) 74.1 (67.5–84.3) 73.0 (67.0–78.1) 74.1 (67.5–95.0) 0.59
Carbohydrate (g/day) 246.0 (67.0) 235.8 (56.5) 255.5 (76.3) 0.44
Fiber (g/day) 17.4 (5.5) 15.9 (3.5) 18.7 (6.7) 0.18
Fat (g/day) 94.3 (35.5) 83.4 (37.6) 104.4 (31.3) 0.11
Intervention diet:
Calories (Kcal/day) 1875.3 (383.4) 2000.6 (293.0) 1758.3 (428.8) 0.09
Protein (g/day) 84.3 (50.0–124.5) 124.6 (122.7–167.0) 50.0 (43.3–58.5) < 0.0001
Carbohydrate (g/day) 230.3 (63.4) 204.0 (40.1) 254.9 (72.2) 0.03
Fiber (g/day) 17.1 (6.3) 15.1 (3.5) 19.0 (7.7) 0.09
Fat (g/day) 93.1 (30.7) 87.2 (25.8) 98.7 (34.6) 0.3
doi:10.1371/journal.pone.0140820.t002
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excretion of indoxyl sulfate (ρ 0.70, P< 0.0001), 24h urinary excretion of indoxyl glucuronide
(ρ 0.44, P 0.02), plasma kynurenic acid (ρ 0.42, P 0.02), 24h urinary excretion of kynurenic acid
(ρ 0.61, P 0.0008) and 24h urinary excretion of quinolinic acid (ρ 0.47, P 0.01). There was no
significant relationship with plasma tryptophan (P 0.18), plasma and 24h urinary excretion of
indole-3-acetic acid (P 0.63 and P 0.27, respectively), and plasma and 24h urinary excretion of
kynurenine (P 0.74 and P 0.17, respectively). Measurements of plasma indoxyl glucuronide
and plasma quinolinic acid were below their limits of detection.
Next, we compared changes in plasma level and 24h urinary excretion of the various trypto-
phan metabolites in the HP vs. LP group (Fig 2), observing a significant increase in plasma
level and 24h urinary excretion of indoxyl sulfate (P 0.004 and P 0.001, respectively), 24h uri-
nary excretion of indoxyl glucuronide (P 0.01), 24h urinary excretion of kynurenic acid (P
0.006) and 24h urinary excretion of quinolinic acid (P 0.02).
Phenolic metabolites
The influence of dietary protein intake was also explored with respect to phenolic metabolites.
Changes in protein intake were correlated with changes in plasma level and 24h urinary excre-
tion of these compounds, only observing a significant relationship with 24h urinary excretion
of p-cresyl sulfate (ρ 0.40, P 0.04). There was no significant correlation with plasma p-cresyl
sulfate (P 0.28), plasma and 24h urinary excretion of p-cresyl glucuronide (P 0.49 and P 0.22,
respectively), plasma and 24h urinary excretion of phenyl sulfate (P 0.25 and P 0.26, respec-
tively), and 24h urinary excretion of phenyl glucuronide (P 0.37). Measurements of plasma and
urine phenylacetic acid, and plasma phenyl glucuronide were below their limits of detection.
In addition, changes in plasma level and 24h urinary excretion were compared in the HP vs.
LP group (Fig 3). We noted an increasing, though not formally significant, trend in 24h urinary
excretion of p-cresyl sulfate (P 0.07). However, there were no between-group differences with
respect to the other metabolites.
Preclinical study
Mice were subjected to either a high protein or a control diet with measurement of plasma sam-
ples after intervention (Fig 4). At baseline and after intervention, there were no differences in
body weight between both groups (P 0.27 and P 0.38, respectively). With respect to the trypto-
phan metabolites, we observed significantly lower levels of plasma tryptophan (P 0.03) and
Fig 1. Protein intake and urea. Influence of a high vs. low protein diet on change in plasma urea and 24h urinary excretion of urea.
doi:10.1371/journal.pone.0140820.g001
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indole-3-acetic acid (P 0.02) in the HP group with also a trend of higher levels of plasma indoxyl
sulfate (P 0.08) and lower levels of plasma kynurenine (P 0.06). Measurements of plasma quinoli-
nic acid and indoxyl glucuronide were below their limits of detection. Furthermore, with regard
to the phenolic metabolites, we observed significantly higher levels of plasma p-cresyl glucuro-
nide (P 0.03), phenyl sulfate (P 0.004) and phenylacetic acid (P 0.01) in the HP group.
Fig 2. Protein intake and tryptophanmetabolites. Influence of a high vs. low protein diet on change in plasma level and 24h urinary excretion of
tryptophan metabolites.
doi:10.1371/journal.pone.0140820.g002
Fig 3. Protein intake and phenolic metabolites. Influence of a high vs. low protein diet on change in plasma level and 24h urinary excretion of phenolic
metabolites.
doi:10.1371/journal.pone.0140820.g003
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Discussion
In this study, we investigated the influence of dietary protein intake on the mammalian meta-
bolome, focusing on selected tryptophan and phenolic metabolites. The key findings are: (i)
protein intake influences mammalian plasma levels and generation of various metabolites; (ii)
protein intake interferes with both the endogenous and colonic microbial metabolism; (iii)
Fig 4. Protein intake andmetabolites in mice. Influence of high protein vs. control diet on plasma level of tryptophan and phenolic metabolites in mice.
doi:10.1371/journal.pone.0140820.g004
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substantial differences are observed between human and mouse metabolic response to protein
intake.
Although increasingly used in the treatment of obesity, the long term health effects of high
protein diets are still unclear [2, 3]. Additionally, there has been an historical interest in low
protein diets in the treatment of patients with CKD [5]. However, the influence of dietary pro-
tein intake on the mammalian metabolome is not well understood, although it can be hypothe-
sized that potential health effects are also mediated by changes in specific metabolites.
Therefore, we investigated the influence of dietary protein intake on the mammalian meta-
bolome by allocating healthy subjects and mice to a high protein or a low protein (human)/
control (mice) diet, focusing on selected tryptophan and phenolic compounds. In human sub-
jects, we observed significant changes in plasma levels and generation of indoxyl sulfate,
indoxyl glucuronide, kynurenic acid, quinolinic acid, and to a lesser extent, p-cresyl sulfate (all
higher in HP group), pointing to an impact of protein intake on solutes derived from both
endogenous and colonic microbial metabolism. Regarding the endogenous metabolites, higher
levels of kynurenic acid have already been associated with inflammation and cardiovascular
disease in the general population, as well as in patients with renal dysfunction [10, 26]. In addi-
tion, kynurenic acid and quinolinic acid have also been related with development of CKD [13].
The relevance of the colonic microbial metabolites have been mainly demonstrated in patients
with pre-existing renal disease [14–18, 20], although recent findings also suggest the impor-
tance of these solutes independent of or preceding renal dysfunction [27, 28].
The significant increase in plasma levels and generation of indoxyl sulfate in the high vs.
low protein diet group are in agreement with a study of Patel et al., demonstrating higher uri-
nary excretion of indoxyl sulfate in omnivores vs. vegetarians with higher protein intake
observed in omnivores [29]. On the other hand, we could only note a trend of higher levels of
p-cresyl sulfate in the high vs. low protein diet group, while there was also a substantially higher
generation of p-cresyl sulfate in the group of omnivores in the abovementioned study. This
apparent discrepancy may be explained by the concomitant lower intake of vegetables in the
omnivores, while fiber intake was kept constant in the current study. Interestingly, a recent
study exploring the effects of prebiotics on serum levels of p-cresyl sulfate and indoxyl sulfate
in hemodialysis patients could also demonstrate a decreasing effect on serum p-cresyl sulfate,
but not on indoxyl sulfate [30]. This may suggest that absolute and relative differences in pro-
tein and fiber intake, besides other, yet unknown, dietary or microbial factors are responsible
for differential changes in generation of these two colonic microbial metabolites.
Concomitantly, we explored the influence of dietary protein intake in mice, observing sig-
nificant changes in plasma levels of tryptophan, indole-3-acetic acid (all lower in HP group), p-
cresyl glucuronide, phenyl sulfate and phenylacetic acid (all higher in HP group), as well as a
clear trend of higher levels of plasma indoxyl sulfate and lower levels of plasma kynurenine. As
metabolite changes were markedly different between human subjects and mice, these findings
suggest inter-species differences in not only the endogenous metabolism, but also in the colonic
microbial metabolism. Regarding the endogenous metabolites, although there is substantial
genetic homology between mice and human, there are still notable differences in gene expres-
sion, also causing important differences in the endogenous metabolism of xenobiotics [31] and
possibly explaining the dissimilar effect of protein intake on the endogenous metabolites mea-
sured in the current study. Furthermore, while it is assumed that mouse and human models
share a common core gut microbial composition with respect to the phylum and genus levels,
there are still substantial dissimilarities in the bacterial relative abundance [32], which, besides
environmental factors, could explain inter-species differences in the fecal metabolome [33],
and therefore also the differential impact of dietary protein intake on plasma levels of the
microbial metabolites in this study. Although this may question the feasibility of translating
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mouse to human models of colonic protein fermentation, especially with respect to protein
intake, potential human-mouse dissimilarities due to differences in type and/or amount of
ingested protein (e.g., 45% relative protein intake in HP mice group vs. target of 25% in HP
human group) have to be excluded.
As this study only included healthy subjects and animals, the influence of dietary protein
intake on the metabolome in patients with CKD remains to be elucidated. While a recent study
has suggested that a protein diet of 0.3 g/kg/day reduced indoxyl sulfate levels in patients with
CKD stage 3 [34], the impact on other metabolites requires further study. In addition, whether
a more modest reduction in protein intake to 0.8 g/kg/day, as generally recommended in order
to offset the risk of malnutrition [35], has the same effect on these metabolites is unknown. It
must also be noted that the protein assimilation process in the small intestine is impaired due
to renal failure, causing an increased colonic availability of protein, thereby promoting protein
fermentation [36]. Although it can, therefore, be hypothesized that similar changes in dietary
protein intake have a more pronounced effect on colonic microbial metabolism in CKD
patients, this needs to be proven.
There are limitations to our study. First, we investigated the influence of dietary protein
intake on the mammalian metabolome by focusing on selected tryptophan and phenolic com-
pounds. As samples were not analyzed by an untargeted metabolomic approach, the effect of
protein intake on other metabolites could not be derived. Second, our study population solely
consisted of healthy subjects of Caucasian origin. Care must be taken to extrapolate our data to
other populations. Finally, as there were no measurements of urine samples in mice, we could
only investigate the influence of protein intake on their plasma levels, not on urinary excretion
rates. Still, we do not expect that this would have altered our main findings.
Conclusions
We demonstrated that dietary protein intake affects the mammalian metabolome by interfer-
ence with both the endogenous and colonic microbial metabolism. Metabolite changes are dis-
similar between human subjects and mice, pointing to inter-species metabolic differences with
respect to protein intake. The relevance of these findings to the general population as well as
patients with CKD needs further investigation.
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